May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Effect of the P2Y14 Receptor Agonist, UDP-Glucose, on Intraocular Pressure (IOP) in Glaucomatous Monkey Eyes
Author Affiliations & Notes
  • S.M. Podos
    Ophthalmology, Mt Sinai School of Medicine, New York, NY, United States
  • R. Wang
    Ophthalmology, Mt Sinai School of Medicine, New York, NY, United States
  • J.L. Boyer
    Inspire Pharmaceuticals, Inc., Durham, NC, United States
  • B.R. Yerxa
    Inspire Pharmaceuticals, Inc., Durham, NC, United States
  • J.B. Serle
    Inspire Pharmaceuticals, Inc., Durham, NC, United States
  • Footnotes
    Commercial Relationships  S.M. Podos, Inspire Pharmaceuticals, Inc. F, C; Pharmacia C; Alcon Laboratories, Inc. C; R. Wang, None; J.L. Boyer, Inspire Pharmaceuticals, Inc. E; B.R. Yerxa, Inspire Pharmaceuticals, Inc. E; J.B. Serle, Inspire Pharmaceuticals, Inc. F; Alcon Laboratories, Inc. C; Allergan, Inc. C; Merck & Co., Inc. C.
  • Footnotes
    Support  Inspire Pharmaceuticals Inc, Durham, NC, NIH Grant EY 01867, Unrestricted Grant from RPB
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 4404. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S.M. Podos, R. Wang, J.L. Boyer, B.R. Yerxa, J.B. Serle; Effect of the P2Y14 Receptor Agonist, UDP-Glucose, on Intraocular Pressure (IOP) in Glaucomatous Monkey Eyes . Invest. Ophthalmol. Vis. Sci. 2003;44(13):4404.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: The UDP-glucose receptor (P2Y14 receptor) is a recently identified member of the nucleotide receptor family. This study evaluates the effect of topical application of UDP-glucose on IOP in monkey eyes with laser-induced unilateral glaucoma. Methods: A multiple-dose study was performed in 8 glaucomatous monkey eyes. One 25 µl drop of UDP-glucose (3%) was applied topically to the glaucomatous eye at 9:30 a.m. and 3:30 p.m. for 5 consecutive days. IOP was measured hourly for 6 hrs beginning at 9:30 a.m. for one baseline day, one vehicle-treated day, and treatment days 1, 3, and 5 with UDP-glucose. Results: Compared to vehicle treatment, twice daily administration of UDP-glucose for 5 days reduced (p<0.05) IOP from 1 hr to 4 hr after the first dose and for at least 6 hrs after the fifth dose. The maximum reduction (p<0.001) of IOP occurred 2 hrs after morning dosing, and was 3.3 ± 0.6 mm Hg (9%) (mean ± SEM) on day 1, 3.8 ± 0.5 mmHg (10%) on day 3, and 5.0 ± 0.6 mmHg (14%) on day 5. The ocular hypotensive effect increased with repeated dosing. The IOP reduction was greater (p<0.05) at 5 and 6 hrs on day 3 compared to day 1 of treatment, and at 0 and 2 hours on day 5 compared to day 3 of treatment. Adverse ocular or systemic side effects were not observed during the 5 days of treatment. Conclusion: UDP-glucose reduces IOP in glaucomatous monkey eyes. Additional investigations of this nucleotide receptor agonist are warranted.

Keywords: animal model • intraocular pressure • pharmacology 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×